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To the Editor
In a recent manuscript entitled “Haploidentical transplant for patients with relapse after first allograft”, 
Srour et al. reported on 29 patients that underwent an haploidentical transplantation (haplo-SCT) for 
relapse after a first allogeneic SCT for different hematological malignancies, mostly AML, with a 3-year 
overall survival (OS) of 40%. Moreover, they found that lower comorbidity index (HCT-CI) and lack of 
donor-specific anti-HLA antibodies were correlated with a significantly better outcome (3-year OS 60% in 
patients with HCT-CI < 3 and no detectable antibodies).1
Prompted by this remarkable outcome, we reviewed our database and identified 19 patients (7 males and 
12 females) who received haplo-SCT for relapse after an allogeneic SCT between 2009 and 2019. Median 
age at haplo-SCT was 44 years (range: 23-72; majority of patients had acute leukemia (AML 13 and ALL 4, 
respectively), one patient had myelofibrosis (MF) and one Hodgkin lymphoma (HL). Median time from 
first SCT to relapse was 8 months (range: 3-34); type of first transplant was matched related donor in 6 
(31.5%), matched unrelated donor in 11 (58%) and haploidentical in 2 (10.5%). Disease status at haplo-SCT 
was complete remission in 3 patients (16%) and active disease in 16 (84%), median HCT-CI was 2 (range: 
1-5) and 7 patients (37%) had an HCT-CI ≥3. Stem cells source was peripheral blood (PB) in 15 cases (79%) 
and bone marrow (BM) in 4 (21%), conditioning regimen was myeloablative in 2 (10%) and reduced 
intensity in 17 (90%). GVHD prophylaxis consisted of post-transplantation cyclophosphamide, 
mycophenolate mofetil and tacrolimus.
With a median follow-up of 30 months (range: 12-64), 18 patients (95%) died, with a median OS of 8 
months (95% confidence interval (CI): 2-8) and a 1-year OS of 16% (95% CI: 4-35) (Figure 1A). Cause of 
death was disease relapse/progression in 14 cases (78%) and non-relapse mortality in 4 (22%). We did not 
find any significant difference in survival according to age at transplant (p=0.40), disease status (p=0.27), 
HCT-CI (p=0.86), stem cell source (p=0.88) or conditioning regimen (p=0.78). The only factor associated 
with a shorter OS was diagnosis of AML: median survival after haplo-SCT was 6 months in the 13 AML 
cases compared to 13 months for other malignancies (p=0.003) (Figure 1B). The difference was confirmed 
also excluding the two cases with MF and HD, as median survival for the 4 ALL patients was 13 months 
(p=0.02). 
Despite being comparable for most of patients and transplant characteristics, our data only partially 
confirm the brilliant results reported from colleagues at M. D. Anderson: while median OS was similar (8 
months), our 1-year survival was only 16% compared to 40%. The only apparent difference between the 
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compared to 31%). If stem cell source may have an impact on long-term survival after haplo-SCT is still to 
be defined: a recent study on over 450 patients receiving an haplo-SCT for lymphoma did not find any 
difference in OS for PB or BM.2 With the limits of a very small sample size, we observed a superior 
outcome of a second haplo-SCT in ALL patients compared to AML ones, despite similar patients and 
transplant features. If this difference is due to different disease biology or to other factors need further 
investigations and confirmation in larger studies.
In evaluating the role of a second haplo-SCT, we must keep in mind that the outcome of patients relapsing 
after an allogeneic SCT is generally poor. A study from the IBMTR on 1788 AML patients relapsing after a 
median of 7 months from an allogeneic SCT: 1231 patients (69%) received intensive therapy, with a 1-year 
survival of 23%; survival probability was directly associated with length of time from SCT to relapse.3 
Motabi et al. found, in a cohort of 100 AML or MDS patients relapsing after allogeneic transplant, a 
median OS of 6 month with intensive chemotherapy and 3.9 months with hypomethylating agents.4 
Relapse after allogeneic SCT represent a challenge for hematologists; along with novel agents, such as 
small molecules and monoclonal antibodies, second transplant represent a feasible option and the choice 
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Figure legend
Figure 1. A. Overall survival in the entire population. B. Overall survival for patients with AML and other 
malignancies.
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